NurExone Biologic Statistics
Total Valuation
NRXBF has a market cap or net worth of 41.28 million. The enterprise value is 40.69 million.
| Market Cap | 41.28M |
| Enterprise Value | 40.69M |
Important Dates
The next estimated earnings date is Tuesday, August 26, 2025.
| Earnings Date | Aug 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 80.01M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +44.76% |
| Shares Change (QoQ) | +3.55% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 75.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 31.37 |
| P/TBV Ratio | 31.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.02 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -8.39 |
Financial Position
The company has a current ratio of 2.47, with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.47 |
| Quick Ratio | 1.31 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -222.65 |
Financial Efficiency
Return on equity (ROE) is -234.45% and return on invested capital (ROIC) is -144.67%.
| Return on Equity (ROE) | -234.45% |
| Return on Assets (ROA) | -115.19% |
| Return on Invested Capital (ROIC) | -144.67% |
| Return on Capital Employed (ROCE) | -364.78% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.00% in the last 52 weeks. The beta is -0.03, so NRXBF's price volatility has been lower than the market average.
| Beta (5Y) | -0.03 |
| 52-Week Price Change | -0.00% |
| 50-Day Moving Average | 0.50 |
| 200-Day Moving Average | 0.47 |
| Relative Strength Index (RSI) | 51.71 |
| Average Volume (20 Days) | 25,097 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.79M |
| Pretax Income | -5.80M |
| Net Income | -5.80M |
| EBITDA | -5.70M |
| EBIT | -5.79M |
| Earnings Per Share (EPS) | -0.08 |
Balance Sheet
The company has 588,000 in cash and 31,000 in debt, giving a net cash position of 557,000.
| Cash & Cash Equivalents | 588,000 |
| Total Debt | 31,000 |
| Net Cash | 557,000 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.32M |
| Book Value Per Share | 0.02 |
| Working Capital | 811,000 |
Cash Flow
In the last 12 months, operating cash flow was -4.41 million and capital expenditures -440,000, giving a free cash flow of -4.85 million.
| Operating Cash Flow | -4.41M |
| Capital Expenditures | -440,000 |
| Free Cash Flow | -4.85M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NRXBF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -44.76% |
| Shareholder Yield | n/a |
| Earnings Yield | -14.05% |
| FCF Yield | -11.75% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |